JP2008540536A - 心疾患の患者における補助治療としての細胞性心筋形成術 - Google Patents
心疾患の患者における補助治療としての細胞性心筋形成術 Download PDFInfo
- Publication number
- JP2008540536A JP2008540536A JP2008511225A JP2008511225A JP2008540536A JP 2008540536 A JP2008540536 A JP 2008540536A JP 2008511225 A JP2008511225 A JP 2008511225A JP 2008511225 A JP2008511225 A JP 2008511225A JP 2008540536 A JP2008540536 A JP 2008540536A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- cells
- treating
- heart
- left ventricular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001413 cellular effect Effects 0.000 title claims abstract description 72
- 208000019622 heart disease Diseases 0.000 title claims abstract description 44
- 238000002560 therapeutic procedure Methods 0.000 title description 9
- 206010019280 Heart failures Diseases 0.000 claims abstract description 96
- 210000002216 heart Anatomy 0.000 claims abstract description 88
- 230000002861 ventricular Effects 0.000 claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 66
- 238000011282 treatment Methods 0.000 claims abstract description 62
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 36
- 230000000302 ischemic effect Effects 0.000 claims abstract description 28
- 206010007559 Cardiac failure congestive Diseases 0.000 claims abstract description 10
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 266
- 210000004683 skeletal myoblast Anatomy 0.000 claims description 59
- 230000002107 myocardial effect Effects 0.000 claims description 48
- 230000000747 cardiac effect Effects 0.000 claims description 41
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 40
- 230000001605 fetal effect Effects 0.000 claims description 17
- 230000001684 chronic effect Effects 0.000 claims description 16
- 230000001154 acute effect Effects 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 8
- 210000001185 bone marrow Anatomy 0.000 claims description 7
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 208000009525 Myocarditis Diseases 0.000 claims description 5
- 230000036772 blood pressure Effects 0.000 claims description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 3
- 201000000057 Coronary Stenosis Diseases 0.000 claims description 3
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 3
- 208000018578 heart valve disease Diseases 0.000 claims description 3
- 210000003494 hepatocyte Anatomy 0.000 claims description 3
- 238000002562 urinalysis Methods 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 abstract description 88
- 210000004165 myocardium Anatomy 0.000 abstract description 71
- 230000004217 heart function Effects 0.000 abstract description 41
- 238000011084 recovery Methods 0.000 abstract description 19
- 239000003814 drug Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 9
- 238000001356 surgical procedure Methods 0.000 abstract description 4
- 210000003098 myoblast Anatomy 0.000 description 100
- 238000002347 injection Methods 0.000 description 79
- 239000007924 injection Substances 0.000 description 79
- 241001465754 Metazoa Species 0.000 description 67
- 230000004083 survival effect Effects 0.000 description 48
- 230000006870 function Effects 0.000 description 36
- 230000004087 circulation Effects 0.000 description 34
- 238000013519 translation Methods 0.000 description 28
- 206010061216 Infarction Diseases 0.000 description 25
- 241001494479 Pecora Species 0.000 description 24
- 238000007634 remodeling Methods 0.000 description 24
- 230000007574 infarction Effects 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 230000001976 improved effect Effects 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 20
- 208000033774 Ventricular Remodeling Diseases 0.000 description 17
- 239000002870 angiogenesis inducing agent Substances 0.000 description 17
- 230000003833 cell viability Effects 0.000 description 16
- 230000006872 improvement Effects 0.000 description 16
- 230000007774 longterm Effects 0.000 description 16
- 210000000038 chest Anatomy 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 210000002027 skeletal muscle Anatomy 0.000 description 15
- 210000000130 stem cell Anatomy 0.000 description 15
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 14
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 208000031225 myocardial ischemia Diseases 0.000 description 14
- 210000000107 myocyte Anatomy 0.000 description 14
- 238000010186 staining Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 210000001087 myotubule Anatomy 0.000 description 12
- 230000001023 pro-angiogenic effect Effects 0.000 description 12
- 210000004351 coronary vessel Anatomy 0.000 description 11
- 238000002592 echocardiography Methods 0.000 description 11
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 11
- 210000003365 myofibril Anatomy 0.000 description 11
- 241000282887 Suidae Species 0.000 description 10
- 230000002238 attenuated effect Effects 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 229910052741 iridium Inorganic materials 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 231100000241 scar Toxicity 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 230000010339 dilation Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 208000028867 ischemia Diseases 0.000 description 9
- XEPXGZZWVKNRGS-GQYPCLOQSA-N n-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]octanamide Chemical compound CCCCCCCC(=O)NC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XEPXGZZWVKNRGS-GQYPCLOQSA-N 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000008439 repair process Effects 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 8
- 230000033115 angiogenesis Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 210000000663 muscle cell Anatomy 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 239000004698 Polyethylene Substances 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 230000004064 dysfunction Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 7
- 230000000877 morphologic effect Effects 0.000 description 7
- 230000001172 regenerating effect Effects 0.000 description 7
- 238000004904 shortening Methods 0.000 description 7
- 240000002989 Euphorbia neriifolia Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 206010003119 arrhythmia Diseases 0.000 description 6
- 230000006793 arrhythmia Effects 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 210000005003 heart tissue Anatomy 0.000 description 6
- 230000000004 hemodynamic effect Effects 0.000 description 6
- 208000037906 ischaemic injury Diseases 0.000 description 6
- 238000013507 mapping Methods 0.000 description 6
- 238000001964 muscle biopsy Methods 0.000 description 6
- 230000010016 myocardial function Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102000001045 Connexin 43 Human genes 0.000 description 5
- 108010069241 Connexin 43 Proteins 0.000 description 5
- 206010013012 Dilatation ventricular Diseases 0.000 description 5
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000002399 angioplasty Methods 0.000 description 5
- 238000007675 cardiac surgery Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 210000001105 femoral artery Anatomy 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 210000005240 left ventricle Anatomy 0.000 description 5
- 230000036723 left ventricular dilatation Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- -1 2'-deoxyribose Chemical compound 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- 102000008076 Angiogenic Proteins Human genes 0.000 description 4
- 108010074415 Angiogenic Proteins Proteins 0.000 description 4
- 206010007558 Cardiac failure chronic Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000002491 angiogenic effect Effects 0.000 description 4
- 238000002583 angiography Methods 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 206010007625 cardiogenic shock Diseases 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000002064 heart cell Anatomy 0.000 description 4
- 238000010562 histological examination Methods 0.000 description 4
- 238000007914 intraventricular administration Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 210000002363 skeletal muscle cell Anatomy 0.000 description 4
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 208000020446 Cardiac disease Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 208000007888 Sinus Tachycardia Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 206010000891 acute myocardial infarction Diseases 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 210000000648 angioblast Anatomy 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000002586 coronary angiography Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003205 diastolic effect Effects 0.000 description 3
- 230000010102 embolization Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 230000003116 impacting effect Effects 0.000 description 3
- 238000002489 impedance cardiography Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000000250 revascularization Effects 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 210000001631 vena cava inferior Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 208000013875 Heart injury Diseases 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 108010065729 Troponin I Proteins 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229950004398 broxuridine Drugs 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 2
- 229960001117 clenbuterol Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000009111 destination therapy Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000011833 dog model Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000001174 endocardium Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000012953 feeding on blood of other organism Effects 0.000 description 2
- 210000000604 fetal stem cell Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 210000003976 gap junction Anatomy 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000012454 limulus amebocyte lysate test Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000005381 potential energy Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000006163 transport media Substances 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 206010047302 ventricular tachycardia Diseases 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- RIFDKYBNWNPCQK-IOSLPCCCSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-imino-3-methylpurin-9-yl)oxolane-3,4-diol Chemical compound C1=2N(C)C=NC(=N)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RIFDKYBNWNPCQK-IOSLPCCCSA-N 0.000 description 1
- RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 description 1
- QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 description 1
- PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- ZUYKJZQOPXDNOK-UHFFFAOYSA-N 2-(ethylamino)-2-thiophen-2-ylcyclohexan-1-one;hydrochloride Chemical compound Cl.C=1C=CSC=1C1(NCC)CCCCC1=O ZUYKJZQOPXDNOK-UHFFFAOYSA-N 0.000 description 1
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- NJERAXSSDSHLGE-UHFFFAOYSA-N 4-(2-fluorophenyl)-1,3,8-trimethyl-6h-pyrazolo[3,4-e][1,4]diazepin-7-one;hydrochloride Chemical compound Cl.N=1CC(=O)N(C)C(N(N=C2C)C)=C2C=1C1=CC=CC=C1F NJERAXSSDSHLGE-UHFFFAOYSA-N 0.000 description 1
- XXSIICQLPUAUDF-TURQNECASA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XXSIICQLPUAUDF-TURQNECASA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 description 1
- UEHOMUNTZPIBIL-UUOKFMHZSA-N 6-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7h-purin-8-one Chemical compound O=C1NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UEHOMUNTZPIBIL-UUOKFMHZSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102100027446 Acetylserotonin O-methyltransferase Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000021479 Cardiovascular injury Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 108010085626 Cymetra Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101600136634 Drosophila melanogaster Troponin I (isoform 6) Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000936718 Homo sapiens Acetylserotonin O-methyltransferase Proteins 0.000 description 1
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 1
- 101000819088 Homo sapiens Transcription factor GATA-6 Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058222 Hypertensive cardiomyopathy Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100032832 Integrin alpha-7 Human genes 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000003430 Mitral Valve Prolapse Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 1
- 102100021382 Transcription factor GATA-6 Human genes 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000001656 angiogenetic effect Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 1
- 229960001590 butorphanol tartrate Drugs 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000008822 capillary blood flow Effects 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 208000005761 carcinoid heart disease Diseases 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 230000010343 cardiac dilation Effects 0.000 description 1
- 230000000876 cardiodynamic effect Effects 0.000 description 1
- 230000003548 cardiotrophic effect Effects 0.000 description 1
- 238000013194 cardioversion Methods 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 108010024084 integrin alpha7 Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007925 intracardiac injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000007576 microinfarct Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000009662 stress testing Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960001594 tiletamine hydrochloride Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67897605P | 2005-05-09 | 2005-05-09 | |
| PCT/US2006/017683 WO2006122005A2 (en) | 2005-05-09 | 2006-05-09 | Cellular cardiomyoplasty as supportive therapy in patients with heart disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008540536A true JP2008540536A (ja) | 2008-11-20 |
| JP2008540536A5 JP2008540536A5 (enExample) | 2009-06-18 |
Family
ID=37397196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511225A Pending JP2008540536A (ja) | 2005-05-09 | 2006-05-09 | 心疾患の患者における補助治療としての細胞性心筋形成術 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8889122B2 (enExample) |
| EP (1) | EP1885185A4 (enExample) |
| JP (1) | JP2008540536A (enExample) |
| AU (1) | AU2006244197A1 (enExample) |
| WO (1) | WO2006122005A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019513691A (ja) * | 2016-02-12 | 2019-05-30 | マリンクロット ホスピタル プロダクツ アイピー リミテッド | 吸入用一酸化窒素の左心補助人工心臓への使用とモニタリング |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9462960B2 (en) * | 2003-02-21 | 2016-10-11 | 3Dt Holdings, Llc | Impedance devices and methods of using the same to obtain luminal organ measurements |
| US8038595B2 (en) * | 2006-01-25 | 2011-10-18 | Beth Israel Deaconess Medical Center | Devices and methods for tissue transplant and regeneration |
| RU2325843C1 (ru) * | 2006-11-28 | 2008-06-10 | Государственное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" | Способ определения критерия для проведения медикаментозной терапии и контроля за эффективностью лечения у больных безболевой ишемией миокарда |
| EP2607898B1 (en) * | 2010-08-17 | 2016-01-20 | Terumo Kabushiki Kaisha | Method for evaluating graft |
| WO2014134532A1 (en) * | 2013-02-28 | 2014-09-04 | Ventrix, Inc. | Methods and compositions for tissue therapy and analysis |
| EP3869195B1 (en) | 2015-03-23 | 2024-03-20 | Astellas Institute for Regenerative Medicine | Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors |
| CA3119068A1 (en) * | 2018-11-08 | 2020-05-14 | University Of Miami | Method of determining responsiveness to cell therapy in dilated cardiomyopathy |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003080798A2 (en) * | 2002-03-21 | 2003-10-02 | Genvec, Inc. | Muscle cells and their use in cardiac repair |
| US6673604B1 (en) * | 1999-07-23 | 2004-01-06 | Diacrin, Inc. | Muscle cells and their use in cardiac repair |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5130141A (en) * | 1988-05-24 | 1992-07-14 | Law Peter K | Compositions for and methods of treating muscle degeneration and weakness |
| US5143842A (en) * | 1988-11-01 | 1992-09-01 | The University Of Colorado Foundation, Inc. | Media for normal human muscle satellite cells |
| WO1990015863A1 (en) | 1989-06-13 | 1990-12-27 | The Board Of Directors Of The Leland Stanford Junior University | Isolation growth and differentiation of human muscle cells |
| US5538722A (en) * | 1989-06-13 | 1996-07-23 | Stanford University | Isolation, growth, differentiation and genetic engineering of human muscle cells |
| WO1991011522A1 (en) * | 1990-01-26 | 1991-08-08 | Baylor College Of Medicine | MUTATED PROMOTER REGION FROM CHICKEN SKELETAL α-ACTIN GENE |
| US5199942A (en) * | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| US5543318A (en) * | 1991-06-12 | 1996-08-06 | Smith; David A. | Method of isolation, culture and proliferation of human atrial myocytes |
| EP0590066A4 (en) * | 1991-06-12 | 1994-12-07 | David A Smith | METHOD FOR INDUCING HUMAN MYOCARDIAL CELL PROLIFERATION. |
| US5405772A (en) * | 1993-06-18 | 1995-04-11 | Amgen Inc. | Medium for long-term proliferation and development of cells |
| WO1995012979A1 (en) | 1993-11-08 | 1995-05-18 | The University Of Southern California | Compositions and methods for transduction of cells |
| US6015671A (en) * | 1995-06-07 | 2000-01-18 | Indiana University Foundation | Myocardial grafts and cellular compositions |
| US5602301A (en) * | 1993-11-16 | 1997-02-11 | Indiana University Foundation | Non-human mammal having a graft and methods of delivering protein to myocardial tissue |
| US6239172B1 (en) * | 1997-04-10 | 2001-05-29 | Nitrosystems, Inc. | Formulations for treating disease and methods of using same |
| US5968983A (en) * | 1994-10-05 | 1999-10-19 | Nitrosystems, Inc | Method and formulation for treating vascular disease |
| EP1407788A2 (en) | 1994-12-13 | 2004-04-14 | Peter K. Law | Myoblast therapy for mammalian diseases |
| WO1996038543A1 (en) | 1995-04-20 | 1996-12-05 | Diacrin, Incorporated | Modified cells and methods for inhibiting xenograft rejection |
| US5919449A (en) * | 1995-05-30 | 1999-07-06 | Diacrin, Inc. | Porcine cardiomyocytes and their use in treatment of insufficient cardiac function |
| US6096532A (en) * | 1995-06-07 | 2000-08-01 | Aastrom Biosciences, Inc. | Processor apparatus for use in a system for maintaining and growing biological cells |
| US6228635B1 (en) * | 1995-06-07 | 2001-05-08 | Aastrom Bioscience, Inc. | Portable cell growth cassette for use in maintaining and growing biological cells |
| US5985653A (en) * | 1995-06-07 | 1999-11-16 | Aastrom Biosciences, Inc. | Incubator apparatus for use in a system for maintaining and growing biological cells |
| US6238908B1 (en) * | 1995-06-07 | 2001-05-29 | Aastrom Biosciences, Inc. | Apparatus and method for maintaining and growth biological cells |
| EP0946713B1 (en) | 1996-10-18 | 2007-03-07 | Universite Laval | Method for in vitro preconditioning of myoblasts before transplantation |
| CA2275436A1 (en) | 1996-12-20 | 1998-07-02 | Curis, Inc. | Treatment of mammalian myocardium with morphogen locally, or with morphogenically-treated myogenic precursor cells |
| US6099832A (en) | 1997-05-28 | 2000-08-08 | Genzyme Corporation | Transplants for myocardial scars |
| US6110459A (en) * | 1997-05-28 | 2000-08-29 | Mickle; Donald A. G. | Transplants for myocardial scars and methods and cellular preparations |
| CA2225185A1 (en) | 1997-08-11 | 1999-02-11 | Peter K. Law | Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities |
| US5972013A (en) * | 1997-09-19 | 1999-10-26 | Comedicus Incorporated | Direct pericardial access device with deflecting mechanism and method |
| US6151525A (en) * | 1997-11-07 | 2000-11-21 | Medtronic, Inc. | Method and system for myocardial identifier repair |
| US6107034A (en) * | 1998-03-09 | 2000-08-22 | The Board Of Trustees Of The Leland Stanford Junior University | GATA-3 expression in human breast carcinoma |
| AU783935B2 (en) | 1999-06-18 | 2006-01-05 | Indiana University Research And Technology Corporation | Cardiomyocytes with enhanced proliferative potential, and methods for preparing and using same |
| EP1221956A2 (en) | 1999-09-30 | 2002-07-17 | McGILL UNIVERSITY | Autologous marrow stem cell (msc) transplantation for myocardial regeneration |
| EP1412479A4 (en) * | 2001-07-12 | 2004-07-28 | Geron Corp | CELLS WITH CARDIOMYOCYTE GENERATION PRODUCED FROM HUMAN PLURIPOTENT STEM CELLS |
| US20050244384A1 (en) * | 2002-04-01 | 2005-11-03 | Law Peter K | Cellular transplantation for heart regeneration |
| US20040191225A1 (en) * | 2002-08-06 | 2004-09-30 | Dinsmore Jonathan H. | Injection system |
| CA2495112A1 (en) | 2002-08-09 | 2004-02-19 | Peter K. Law | Mechanisms of myoblast transfer in treating heart failure |
-
2006
- 2006-05-09 US US11/430,693 patent/US8889122B2/en active Active
- 2006-05-09 WO PCT/US2006/017683 patent/WO2006122005A2/en not_active Ceased
- 2006-05-09 JP JP2008511225A patent/JP2008540536A/ja active Pending
- 2006-05-09 EP EP06759297A patent/EP1885185A4/en not_active Withdrawn
- 2006-05-09 AU AU2006244197A patent/AU2006244197A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6673604B1 (en) * | 1999-07-23 | 2004-01-06 | Diacrin, Inc. | Muscle cells and their use in cardiac repair |
| WO2003080798A2 (en) * | 2002-03-21 | 2003-10-02 | Genvec, Inc. | Muscle cells and their use in cardiac repair |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019513691A (ja) * | 2016-02-12 | 2019-05-30 | マリンクロット ホスピタル プロダクツ アイピー リミテッド | 吸入用一酸化窒素の左心補助人工心臓への使用とモニタリング |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006244197A1 (en) | 2006-11-16 |
| EP1885185A4 (en) | 2010-04-07 |
| US20060276685A1 (en) | 2006-12-07 |
| WO2006122005A3 (en) | 2007-11-01 |
| EP1885185A2 (en) | 2008-02-13 |
| WO2006122005A2 (en) | 2006-11-16 |
| US8889122B2 (en) | 2014-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saito et al. | Transcoronary implantation of bone marrow stromal cells ameliorates cardiac function after myocardial infarction | |
| Min et al. | Significant improvement of heart function by cotransplantation of human mesenchymal stem cells and fetal cardiomyocytes in postinfarcted pigs | |
| López et al. | Wharton's jelly or bone marrow mesenchymal stromal cells improve cardiac function following myocardial infarction for more than 32 weeks in a rat model: a preliminary report | |
| US20070059288A1 (en) | Treatment for heart disease | |
| Ladage et al. | Stimulating myocardial regeneration with periostin Peptide in large mammals improves function post-myocardial infarction but increases myocardial fibrosis | |
| Chiu | Bone-marrow stem cells as a source for cell therapy | |
| US20130041348A1 (en) | Catheter-Based Delivery of Skeletal Myoblasts to the Myocardium of Damaged Hearts | |
| Wang et al. | Cardiac microvascular functions improved by MSC-derived exosomes attenuate cardiac fibrosis after ischemia–reperfusion via PDGFR-β modulation | |
| JP2010285440A (ja) | 治療複合物 | |
| Ciulla et al. | Homing of peripherally injected bone marrow cells in rat after experimental myocardial injury | |
| JP2024133372A (ja) | 心不全の治療方法 | |
| Pagano et al. | On the road to regeneration:“tools” and “routes” towards efficient cardiac cell therapy for ischemic cardiomyopathy | |
| Haider et al. | MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases | |
| Liu et al. | Lysophosphatidic acid protects mesenchymal stem cells against ischemia-induced apoptosis in vivo | |
| US20120020925A1 (en) | Therapeutic Use of Specialized Endothelial Progenitor Cells | |
| US8889122B2 (en) | Cellular cardiomyoplasty as supportive therapy in patients with heart disease | |
| Li et al. | Optimal transplantation strategy using human induced pluripotent stem cell‐derived cardiomyocytes for acute myocardial infarction in nonhuman primates | |
| JP2008519659A (ja) | 静脈閉塞装置および使用法 | |
| Premaratne et al. | Repeated implantation is a more effective cell delivery method in skeletal myoblast transplantation for rat myocardial infarction | |
| Tavakoli et al. | Outcome improvement of cellular cardiomyoplasty using triple therapy: mesenchymal stem cell+ erythropoietin+ vascular endothelial growth factor | |
| Dib et al. | Safety and feasibility of percutaneous autologous skeletal myoblast transplantation in the coil-infarcted swine myocardium | |
| Öztürk et al. | Cardiac stem cell characteristics in physiological and pathological conditions | |
| Tang et al. | Transplantation of 5-azacytidine treated cardiac fibroblasts improves cardiac function of infarct hearts in rats | |
| Lancaster | Development and testing of a tissue engineered cardiac construct for treatment of chronic heart failure | |
| Ladage et al. | Stimulating Myocardial Regeneration with Periostin Peptide in Large Mammals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090424 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090424 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100405 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120117 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120416 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120423 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120516 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120523 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120618 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120703 |